GSK plc (GSK.L)
Develops and sells vaccines, cancer drugs, and medicines to treat diseases worldwide
2,029.00+0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+45.3%
The outlook
GSK sits near the upper end of its 52-week range and above both its 50- and 200-day moving averages, signaling near-term upward momentum. Analyst consensus leans cautiously with a Hold rating, and the average price target sits roughly 5% above the current level. The stock trades at a 14.3 trailing P/E, with modest analyst coverage suggesting limited consensus conviction either way.
What’s behind the score
Analyst consensusHold — 2.6 avg of 20 analysts
Price trendAbove its 50- & 200-day averages
52-week range89% of the way from its 52-week low to high
Price targetAvg target +5% vs current price
Analyst price target
~12-month · 20 analysts2,139.05average target+5.4% vs now
Now 2,029.00
Low 1,455.00High 2,825.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$81.27B
52-wk high
2,282.00
52-wk low
0.00
50-day avg
1,934.12
200-day avg
1,932.85
Trailing P/E
14.3